Announcements Trials
Browse Landscape

Phase

Phase 1 33Phase 1/2 29Phase 2 24Phase 3 4Phase NA 1Phase 4 1Phase 2/3 1

Status

Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 24Carcinoma, Renal Cell 16Stomach Neoplasms 9Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 6Carcinoma, Hepatocellular 6Kidney Neoplasms 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Neoplasms 4Mesothelioma 4Adenocarcinoma Of Esophagus 4Skin Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Anus Neoplasms 3Various Advanced Cancer 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Mesothelioma, Malignant 2Liver Neoplasms 2Hodgkin Disease 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma 2Anal Canal Carcinoma 2Adenocarcinoma 2von Hippel-Lindau Disease 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Prednisone 9Pemetrexed 9Epoetin Alfa 9venetoclax 8atezolizumab 8Fentanyl 8Drug Therapy 8Doxorubicin 8Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Nivolumab × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03937219 2025-09-10

COSMIC-313

Exelixis

Phase 3 Active not recruiting
855 enrolled 12 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT03522246 2025-06-24

ATHENA

pharmaand GmbH

Phase 3 Active not recruiting
1,097 enrolled 26 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT04109066 2025-01-08

CheckMate 7FL

Bristol-Myers Squibb

Phase 3 Completed
521 enrolled 17 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡